Pantoprazole Actavis (Pantoprazole Sodium)

Pantoprazole sodium, the active ingredient in Pantoprazole Actavis, is a proton pump inhibitor presented as a tablet for oral use. It reduces gastric acid secretion and is indicated for the treatment of acid‑related disorders in adult patients.\n\nGNH India supplies Pantoprazole Actavis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Pantoprazole Actavis is a proton pump inhibitor used to manage conditions caused by excess stomach acid.\n\n- Gastro‑esophageal reflux disease (GERD): provides symptomatic relief and promotes healing of erosive esophagitis.\n- Peptic ulcer disease: facilitates ulcer healing and reduces the risk of recurrence.\n- Zollinger‑Ellison syndrome: controls gastric acid hypersecretion associated with this rare endocrine disorder.

Pantoprazole is generally well tolerated, but adverse reactions can occur.\n\nCommon Side Effects:\n- Headache\n- Diarrhea\n- Abdominal pain\n- Nausea\n- Flatulence\n- Constipation\n\nSerious or Rare Side Effects:\n- Severe allergic reaction (anaphylaxis)\n- Clostridioides difficile‑associated colitis\n- Elevated liver enzymes\n- Hypomagnesemia with prolonged use\n- Stevens‑Johnson syndrome or toxic epidermal necrolysis

Before initiating therapy, consider the following precautions.\n\n- Renal or hepatic impairment: adjust therapy based on clinical response.\n- Elderly patients: monitor for increased sensitivity to side effects.\n- Discontinuation: avoid abrupt cessation after long‑term use to reduce rebound acid hypersecretion.\n- Infection risk: be alert for signs of gastrointestinal infections, especially C. difficile.\n- Concomitant medications: review for drugs that may require dose adjustment.\n- Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Pantoprazole may affect the pharmacokinetics of several co‑administered drugs.\n\nMajor Interactions (Avoid):\n- Atazanavir: reduced absorption and antiviral efficacy.\n- Nelfinavir: decreased plasma concentrations.\n- Rilpivirine: diminished exposure leading to therapeutic failure.\n- Clopidogrel: impaired conversion to active metabolite, reducing antiplatelet effect.\n\nModerate Interactions (Monitor Closely):\n- Warfarin: possible increase in INR, monitor coagulation.\n- Digoxin: slight increase in serum levels, observe for toxicity.\n- Methotrexate: reduced clearance, watch for toxicity.\n- Fluconazole and ketoconazole: increased plasma levels of pantoprazole, may require dose adjustment.